Finance Express . . . September 2020 National Medical and Health Industry Financing Summary.

In September, there were 118 cases of financing in the field of medical and health care, with a disclosed amount of about 22.586 billion yuan (up about 13.9% from the previous month), 47 cases of financing of more than 100 million yuan, and a disclosure amount of more than 100 million yuan of about 22.16 billion yuan.
. The sub-sectors with a high number of financing projects are: pharmaceuticals (26, or 22.03 per cent), medical devices (23, or 19.9 per cent), and industrial services (22, or 18.64 per cent).
. Financing projects are concentrated in Shanghai (25), Jiangsu Province (24), Beijing (22), Guangdong Province (18), the total number of financing projects accounted for about 75.42% september financing profile 1.Quantity and scale September medical There were 118 cases of financing in the field of health, with a disclosed amount of about 22.586 billion yuan and 47 cases with a financing amount of more than RMB 100 million, with a total financing amount of about 22.16 billion yuan, accounting for 98.11% of the total financing volume for the month.
disclosed this month that the largest financing was: Minimally Invascope Healthcare (00853. HK) Micro-Creative (Shanghai) Medical Robotics Co., Ltd. completed 3 billion yuan of financing, of which 1.5 billion yuan came from direct capital increase, another 1.5 billion from micro-invasible equity transfer, and the introduction of a number of well-known strategic investors, including Technology Capital, CPE, Bayer Capital, Far Wing Investment, YFonda Capital.
's second-largest financing this month was the announcement of a final subscription agreement with a consortium led by Gao Wei Capital to raise $418m through a private placement (PIPE), the largest PIPE financing ever made in China's biotech sector.
's third-largest financing project this month was the announcement by XtalPi, a digital and intelligent-driven artificial intelligence (AI) drug research and development company, of $318.8 million in round C financing, the highest global funding for AI drug research and development.
This round of investments is jointly led by SoftBank Vision Fund Phase 2, People's Insurance Capital, Chenxing Capital, China Capital, China Merchants International China Merchants Telecom Fund, Mirae Asset (Future Assets), China Securities Investment, CITIC Capital, Haisong Capital, Shunwei Capital, Fangyuan Capital, IMO Ventures, Parkway Fund and many other investors from around the world, Tencent, Sequoia China, China Life Equity Investment, SIG Haina and other early shareholders to continue to invest.
table 1: September medical and health industry financing scale TOP10 project data source: Firestone creation database 2. Financing phase distribution in September, the number of domestic medical and health industry financing projects concentrated in the A-round period before (including angel wheel, Pre-A round, A-wheel, A-wheel, A-wheel, A3 round) total 35 cases, accounting for about 29.66 percent of the total number of projects, 22 round b phases, accounting for 18.64 percent of the total number of projects, 20 equity financing, accounting for about 16.95 percent of the total number of projects, 19 strategic financing, accounting for about 16.1 percent of the total number of projects.
amount of strategic financing in each round of financing amounted to 6,962 million yuan, accounting for about 30.82 percent of the total amount this month.
figure 1: Number and amount of financing for each round in September Data sources: Firestone Creation Database Segment Financing Profile In the segment, the number of financings in the pharmaceutical sector was 26, accounting for 22.03 percent of the total number of financing projects;
overall, drugs and medical devices remain firmly in the top two, regardless of the number of financing projects or the amount of financing.
Figure 2: The amount and amount of financing in the sub-sectors in September Data sources: Firestone Creation Database 1. The largest amount of money in the pharmaceutical sector this month came from the innovative biopharmaceutical developer Tianyi Bio, which signed a final subscription agreement with a consortium of institutional investors to raise $418 million through a private placement (PIPE), the largest PIPE financing in the history of China's biotechnology sector.
the consortium is led by GIC Singapore Government Investment Corporation, Avidity Partners, Orbi Med Obo Capital, Octagon Capital Advisors, Invus, Lake Bleu Clear Pool Capital, Perceptive Advisors, Cormorant Asset Management, Sphera Healthcare and Alyeska Investment Group, L.P.
,940 million yuan in a strategic investment by Tonghua Dongbao, a research and development company for diabetes treatment drugs, with the investor as Dehong Capital.
this round of investors, Dehong Capital, was founded by Liu Haifeng, former co-head of private equity investment in Asia and chief executive of Greater China, focusing on healthcare and other areas.
capital has also recently invested in MFS Technology, Far East Hongxin and other enterprises.
, an innovative pharmaceutical company focused on innovative drug research and development and industrialization in the field of cancer and metabolic diseases, has announced that it has completed nearly 1 billion yuan in round C financing.
The current round of financing by Shenzhen Investment Control, Taige Pharmaceuticals, Huarongde, Sinopharm, Jianyin International, Hongtai Fund, Guohai Innovation, Infininidi, Fang Zhenghesheng, Deno Capital, Qindo Capital, Zhongke Rongxin and other investment institutions to participate.
fund-raising will be mainly used for the company's multiple products in China and overseas global multi-center clinical trials and industrialization, in order to accelerate the layout of the global market for Haitron Pharmaceuticals.
table 2: September part of the financing data sources in the pharmaceutical sector: Firestone Creation Database 2. Medical device financing amount of this month is intelligent minimally invasible medical device manufacturer "micro-invasional medical robot", announced the completion of 3 billion yuan of strategic investment, the investors are High Capital, Far Wing Investment, Esfonda Fund, CPE.
this round of investment is mainly to build a full chain product line, expand the application scenario and build a team.
Minimally Invascopic Medical Robotics, a wholly-owned subsidiary of Shanghai Micro-Invascopic Medical Devices Group Co., Ltd., focuses on the field of micro-trauma, targeting the industry's cutting-edge development needs, combining intelligent control, robotics, sensing and information technologies, to provide patients with integrated intelligent surgical solutions to save patients' lives or improve their quality of life.
, an early diagnosis product and service provider of tumors, officially announced the completion of round C financing, which took only three months to complete a total of RMB600 million in transactions.
The financing was led by Qingsong Capital, Haisong Capital, Jundo Capital, Channel Capital, Shengyu Investment, Guangzhou Development Zone Fund, Convergence Star Fund, Tianjin Huayi and Xingrui Capital, the original shareholders IDG Capital and Dingyi Investment continued to follow the investment, Huaxing Capital as the exclusive financial advisor.
Smart Medical Technology and Service Provider "Jingyu Shares" completed the D-round 430 million yuan financing, the investors for Tencent Investment (lead investment), Longmen Capital, Deyi Capital, Zhenghai Capital, Meihe Zhongbang, Jiaxing Guangrun.
table 3: September medical device sector part of the financing data source: Firestone Creation Database Financing geographical distribution overview in September, financing projects concentrated in Shanghai, Jiangsu, Beijing, Guangdong, Zhejiang, the total number of financing projects 102, accounting for about 86.44 percent.
, 25 financing projects in Shanghai accounted for 21.19% of the total number of financing projects in the month, 24 financing projects in Jiangsu accounted for 20.34% of the total number of financing projects in the month, 22 financing projects in Beijing accounted for 18.64% of the total number of financing projects in the month, 18 financing projects in Guangdong, accounting for 15.25% of the total number of financing projects in the month, and 13 financing projects in Zhejiang, accounting for 11.02% of the total financing projects in the month.
Figure 3: Number and amount of financing in various regions In September Data source: Firestone Creation Database 1. Shanghai in September, Shanghai disclosed the number of financing and the amount of financing accounted for the first, including a number of heavy-weight financing incidents.
Micro-Invasible Medical Robotics, a manufacturer of smart minimally invasible medical devices, announced the completion of a 3 billion yuan strategic investment, which will be made by Gao Wei Capital, Far Wing Investment, Esfonda Fund and CPE.
this round of investment is mainly to build a full chain product line, expand the application scenario, build a team.
Minimally Invascopic Medical Robotics, a wholly-owned subsidiary of Shanghai Micro-Invascopic Medical Devices Group Co., Ltd., focuses on the field of micro-trauma, targeting the industry's cutting-edge development needs, combining intelligent control, robotics, sensing and information technologies, to provide patients with integrated intelligent surgical solutions to save patients' lives or improve their quality of life.
Bio, an innovative biopharmaceutical developer, has signed a final subscription agreement with a consortium of institutional investors to raise $418m through a private placement (PIPE), the largest PIPE financing ever made in China's biotech sector.
the consortium is led by GIC Singapore Government Investment Corporation, Avidity Partners, Orbi Med Obo Capital, Octagon Capital Advisors, Invus, Lake Bleu Clear Pool Capital, Perceptive Advisors, Cormorant Asset Management, Sphera Healthcare and Alyeska Investment Group, L.P.
small molecule innovative drug developer "Yifang Bio" announced the completion of the D-round financing, the total size of the current round of financing 1 billion, this round of financing led by Gao Yi Ventures, Qiming Ventures, Janchor (JianIndustrial), AIHC Capital, Weiwei China, Deyi Capital, Yifangda Capital and other institutions to invest, the former shareholders Lilly Asia Fund, Obo Capital, Pudong Science and Technology, Shang Capital, China Merchants International and so on continue to increase their holdings.
: September Shanghai medical and health industry partial financing data source: Firestone Creation Database 2. Jiangsu Province this month 24 financing, a total financing amount of about 3,061 million yuan.
cancer immunotherapy maker Keystone Pharmaceuticals has announced a strategic partnership with Pfizer, which will buy 115,928,803 keystone shares for a total of $200 million at $1.725 per share, or about HK$13.37 per share.
Pfizer will own 9.9 per cent of Keystone Pharmaceuticals under such equity investments.
-humanized antibody drug developer "Collecting Drug Kang" completed more than 400 million yuan B round of financing, the current round of financing led by Gao Yu Ventures, Yunfeng Fund, Morgan Stanley Investment Management Fund, Sequoia Capital China Fund, Taifu Capital and other funds to participate in the investment, this is after the "Collecting Drug Kang" 2019 160 million yuan A round of financing after the new round of financing.
this round of funds will be mainly used to promote the global production capacity layout and the construction of new technology research and development platform.
medical service provider Meijie Translational Medicine announced the completion of 350 million yuan B round of financing.
This round of financing by the original shareholder Qiming Venture Capital, China Pharmaceutical Capital, Qingsong Capital and Borun Investment and Investment, round A investors Quancheng Capital, Anjie Investment, etc. continue to invest, Yikai Capital as the exclusive financial adviser.
this round of financing will be mainly used to expand the whole platform of translational medicine, increase research and development of accompanying diagnostic products, accelerate product registration and sales network, expand overseas research and development and service capabilities, and improve commercial promotion.
Table 5: September Jiangsu Province medical and health industry part of the financing data source: Firestone Creation Database 3. Beijing this month, Beijing area financing projects 22, of which 9 disclosed the amount of financing, disclosed a total of about 2.633 billion yuan.
Animal genetic testing agency "100 Osaitu" completed 970 million yuan of D-plus round of financing, the current round of financing by China Merchants Bank International, China Investment Ventures, National Life Equity, Herb Capital, TongTron Weiye and Baifu Capital and other investment.
the financing will be used mainly to support the company's "thousands of rats against" program rapid implementation.
with the progress of the program, "100 Osaitu" will work with many domestic and foreign pharmaceutical research and development enterprises to accelerate the process of innovative drug research and development to market.
700 million RMB D-plus round of financing through Zero-Yuan Technology, a one-stop solution provider for cancer big data.
the new investors in this financing are ZHONGC Capital, Broadband Capital CBC, Youshan Capital, Jinnanhai River Broadband Zhihui Industry Fund, etc., and the early investors continue to follow suit.
This round of funds will be used to further focus on the core business development of new drugs for cancer, establish a patient service system that covers the patient's entire disease treatment cycle, with Internet hospitals, offline professional clinic pharmacies and clinical recruitment of new drugs as the core, and establish a real-world data platform and innovative insurance payment program to assist in the development of new drugs oncology.
Pharmaceutical Product Research and Development Production and Sales company "First Pass Pharmaceuticals" announced the completion of 280 million yuan C round of financing, investment institutions including Tong spoke fund, China Pharmaceutical Capital, Material Investment, Guoke Jia and Andhoe Tong Ventures.
fund raising is mainly used for preclinical development and clinical research of radiation projects.
will continue to work together to help China's nuclear drug industry develop rapidly and benefit Chinese patients by strengthening cooperation with outstanding enterprises upstream and downstream of the nuclear medicine industry chain.
table 6: September Beijing area health care industry part of the financing data source: Firestone Creation Database Close September financing cases compared with the amount of financing in August have increased significantly, and unlike most other industries affected by the new crown epidemic, investment in the health care sector this year ushered in a wave of explosive growth.
, Shanghai and Guangdong have always been the key areas to absorb investment, and Jiangsu, which has a number of head enterprises, and Zhejiang, which has accelerated its layout in the field of health care, are also key areas of capital concern.
.